LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial

Antonio Passaro, Byoung Chul Cho, Yan Wang, Barbara Melosky, Raffaele Califano, SH Lee, Nicolas Girard, Karen L. Reckamp, Toshiaki Takahashi, Enriqueta Felip, Ryan D. Gentzler, Sanjay Popat, William N. William, Tao Sun, Shalin Shah, B. Diorio, Roland E. Knoblauch, Joshua Bauml, M.R. García-Campelo, Jing Wang